Outset Medical (NASDAQ:OM) CEO Leslie Trigg Sells 3,361 Shares

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 3,361 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $3.35, for a total value of $11,259.35. Following the completion of the sale, the chief executive officer owned 102,342 shares of the company’s stock, valued at $342,845.70. This represents a 3.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Leslie Trigg also recently made the following trade(s):

• On Wednesday, January 21st, Leslie Trigg sold 2,120 shares of Outset Medical stock. The shares were sold at an average price of $5.05, for a total value of $10,706.00.
• On Tuesday, January 20th, Leslie Trigg sold 11,794 shares of Outset Medical stock. The stock was sold at an average price of $5.12, for a total value of $60,385.28.
• On Wednesday, January 7th, Leslie Trigg sold 1,795 shares of Outset Medical stock. The stock was sold at an average price of $4.27, for a total transaction of $7,664.65.

Outset Medical Price Performance

Shares of OM stock traded down $0.07 during mid-day trading on Friday, reaching $3.46. The company’s stock had a trading volume of 120,908 shares, compared to its average volume of 1,171,142. Outset Medical, Inc. has a 1-year low of $3.10 and a 1-year high of $21.98. The company has a market cap of $63.35 million, a P/E ratio of -0.51 and a beta of 2.08. The company has a debt-to-equity ratio of 0.76, a quick ratio of 5.77 and a current ratio of 6.67. The firm’s 50-day moving average is $4.34 and its two-hundred day moving average is $9.06.

Institutional Trading of Outset Medical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Legal & General Group Plc acquired a new position in Outset Medical during the 2nd quarter valued at about $34,000. Ameritas Investment Partners Inc. bought a new stake in shares of Outset Medical during the second quarter worth approximately $35,000. BNP Paribas Financial Markets lifted its holdings in Outset Medical by 7,013.8% in the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after buying an additional 2,034 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new position in Outset Medical in the second quarter valued at approximately $78,000. Finally, New York State Common Retirement Fund bought a new position in Outset Medical in the second quarter valued at approximately $108,000.

Analysts Set New Price Targets

OM has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a report on Monday, December 29th. Wall Street Zen lowered Outset Medical from a “hold” rating to a “sell” rating in a research note on Sunday, February 8th. BTIG Research reduced their target price on shares of Outset Medical from $17.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $7.00 target price on shares of Outset Medical in a report on Wednesday, December 17th. Finally, Stifel Nicolaus dropped their target price on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $10.00.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.